290 related articles for article (PubMed ID: 33950341)
1. Current experimental therapies for atypical and malignant meningiomas.
Corona AM; Di L; Shah AH; Crespo R; Eichberg DG; Lu VM; Luther EM; Komotar RJ; Ivan ME
J Neurooncol; 2021 Jun; 153(2):203-210. PubMed ID: 33950341
[TBL] [Abstract][Full Text] [Related]
2. Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas.
Maggio I; Franceschi E; Tosoni A; Nunno VD; Gatto L; Lodi R; Brandes AA
CNS Oncol; 2021 Jun; 10(2):CNS72. PubMed ID: 34015955
[TBL] [Abstract][Full Text] [Related]
3. Role of adjuvant radiotherapy in atypical (WHO grade II) and anaplastic (WHO grade III) meningiomas: a systematic review.
Delgado-López PD; Corrales-García EM
Clin Transl Oncol; 2021 Feb; 23(2):205-221. PubMed ID: 32651886
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and toxicity of particle radiotherapy in WHO grade II and grade III meningiomas: a systematic review.
Wu A; Jin MC; Meola A; Wong HN; Chang SD
Neurosurg Focus; 2019 Jun; 46(6):E12. PubMed ID: 31153145
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant radiation for WHO grade II and III intracranial meningiomas: insights on survival and practice patterns from a National Cancer Registry.
Brown DA; Goyal A; Kerezoudis P; Alvi MA; Himes BT; Bydon M; Van Gompel JJ; Chaichana KL; Quiñones-Hinojosa A; Burns TC; Yan E; Parney IF
J Neurooncol; 2020 Sep; 149(2):293-303. PubMed ID: 32860156
[TBL] [Abstract][Full Text] [Related]
6. Determining the role of adjuvant radiotherapy in the management of meningioma: a Surveillance, Epidemiology, and End Results analysis.
Reddy AK; Ryoo JS; Denyer S; McGuire LS; Mehta AI
Neurosurg Focus; 2019 Jun; 46(6):E3. PubMed ID: 31153148
[TBL] [Abstract][Full Text] [Related]
7. Current treatment options for meningioma.
Apra C; Peyre M; Kalamarides M
Expert Rev Neurother; 2018 Mar; 18(3):241-249. PubMed ID: 29338455
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of adjuvant radiotherapy for intracranial atypical and malignant meningiomas.
Unterberger A; Nguyen T; Duong C; Kondajji A; Kulinich D; Yang I
J Neurooncol; 2021 Apr; 152(2):205-216. PubMed ID: 33635510
[TBL] [Abstract][Full Text] [Related]
9. Management of Atypical and Anaplastic Meningiomas.
Buttrick S; Shah AH; Komotar RJ; Ivan ME
Neurosurg Clin N Am; 2016 Apr; 27(2):239-47. PubMed ID: 27012388
[TBL] [Abstract][Full Text] [Related]
10. Survival and Prognostic Predictors of Anaplastic Meningiomas.
Masalha W; Heiland DH; Delev D; Fennell JT; Franco P; Scheiwe C; Mercas BI; Mader I; Schnell O; Grauvogel J
World Neurosurg; 2019 Nov; 131():e321-e328. PubMed ID: 31356972
[TBL] [Abstract][Full Text] [Related]
11. Related mechanisms, current treatments, and new perspectives in meningioma.
Inetas-Yengin G; Bayrak OF
Genes Chromosomes Cancer; 2024 May; 63(5):e23248. PubMed ID: 38801095
[TBL] [Abstract][Full Text] [Related]
12. Advances in meningioma therapy.
Norden AD; Drappatz J; Wen PY
Curr Neurol Neurosci Rep; 2009 May; 9(3):231-40. PubMed ID: 19348712
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma.
Hemmati SM; Ghadjar P; Grün A; Badakhshi H; Zschaeck S; Senger C; Acker G; Misch M; Budach V; Kaul D
Radiat Oncol; 2019 Sep; 14(1):160. PubMed ID: 31477146
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.
Sioka C; Kyritsis AP
J Neurooncol; 2009 Mar; 92(1):1-6. PubMed ID: 19023520
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and treatment of atypical and anaplastic meningiomas: a review.
Modha A; Gutin PH
Neurosurgery; 2005 Sep; 57(3):538-50; discussion 538-50. PubMed ID: 16145534
[TBL] [Abstract][Full Text] [Related]
16. World Health Organization Grade III Meningiomas: A Retrospective Study at an Academic Medical Center.
Sá-Marta E; Alves JL; Rebelo O; Barbosa M
World Neurosurg; 2021 May; 149():e877-e893. PubMed ID: 33516862
[TBL] [Abstract][Full Text] [Related]
17. Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?
Góes P; Santos BFO; Suzuki FS; Salles D; Stávale JN; Cavalheiro S; de Paiva Neto MA
J Neurooncol; 2018 Apr; 137(2):331-336. PubMed ID: 29270884
[TBL] [Abstract][Full Text] [Related]
18. Advances in the systemic therapy for recurrent meningiomas and the challenges ahead.
Li Y; Drappatz J
Expert Rev Neurother; 2023; 23(11):995-1004. PubMed ID: 37695700
[TBL] [Abstract][Full Text] [Related]
19. Clear cell histology portends a worse prognosis than other WHO grade II histologies.
Soni P; Shao J; Momin A; Lopez D; Angelov L; Mohammadi AM; Barnett GH; Recinos PF; Kshettry VR
J Neurooncol; 2021 Jan; 151(2):307-312. PubMed ID: 33398533
[TBL] [Abstract][Full Text] [Related]
20. Atypical and malignant meningiomas: Considerations for treatment and efficacy of radiotherapy.
Cain SA; Smoll NR; Van Heerden J; Tsui A; Drummond KJ
J Clin Neurosci; 2015 Nov; 22(11):1742-8. PubMed ID: 26213286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
